A Phase 3 interventional study of Dapagliflozin and Placebo in Acute Myocardial Infarction and Heart Failure, sponsored by AstraZeneca. Completed at 103 sites in 2 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.
Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 5th largest by enrollment, is one of 8 that started in 2020, is one of 16 in phase 3, and was the 16th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.
Browse Heart Failure studies →15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in Hong Kong
Ages 12+
Yale University · Sites in United States
Ages 18–85 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 32 more countries
Ages 40+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 14 · Phase 3 20 · Phase 4 22
First in 2015; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,017 is above the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 100 across the 59 interventional studies. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 59 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
64 studies in Heart Failure by AstraZeneca: 6 open now, 8 under way, 3 of them phase 3. Of 54 finished, 14 (26%) have results posted.
Among the 64 studies in Heart Failure by AstraZeneca, this one is the 7th largest by enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2020, is one of 15 in phase 3, and was the 34th registered.
AstraZeneca’s Heart Failure studies by the year they started, since 1999.
4 of the studies testing dapagliflozin in Heart Failure that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06304857Phase 34th Military Clinical Hospital with Polyclinic, PolandCardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL | 2026-12-31 |
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06578520Fundación para la Investigación del Hospital Clínico de ValenciaEffect of the Use of Dapagliflozin in Patients With Refractory Heart Failure | 2026-12-01 |
| NCT06762964Mayo ClinicCAMEO-FONTAN -Dapagliflozin in the Failing Fontan Circulation | 2027-02 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing dapagliflozin in Heart Failure, from their registry updates:
Among AstraZeneca’s 64 in Heart Failure:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the effect of dapagliflozin versus placebo, given once daily in addition to Standard of Care (SoC) therapies for patients with myocardial infarction (MI), for hospitalisation for heart failure (HHF), cardiovascular (CV) death, and other cardiometabolic outcomes.
This is a multicentre, parallel group double-blind, placebo-controlled phase 3 registry-based randomised controlled trial (R-RCT) in patients without diabetes presenting with myocardial infarction (MI) (ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI)) and evidence of impaired regional or global LV systolic function or definite evidence of Q wave MI on ECG. In the study the effect of dapagliflozin versus placebo, given once daily in addition to SoC therapy will be evaluated for the hospitalisation for HF, CV death, and other cardiometabolic outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be randomized 1:1 to either dapagliflozin or placebo
Drug: Dapagliflozin
Placebo matching dapagliflozin
Drug: Placebo
Dapagliflozin 10 mg tablets given once daily, per oral use
Also known as: Forxiga TM, Farxiga TM
Placebo matching dapagliflozin 10 mg tablets given once daily, per oral use
Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set)
Study participants received dapagliflozin 10 mg or matching placebo, given once daily in addition to SoC. Overall, the mean study duration was 12.0 months (time in study until last visit) with an accumulated 4023.9 participant-years. The maximum study duration for any participant was 29 months. "Number of Events" for NYHA corresponds to the number of participants with a non-missing value for NYHA functional class at the last visit, and that all participants with a non-missing value take part in the analysis comparing their NYHA class value with all other participants with a NYHA value, according to the win-ratio method.
Time frame: 29 months
| Milestone | Dapa 10 mg | Placebo |
|---|---|---|
| Started | 2019 | 1998 |
| Completed | 2014 | 1994 |
| Not completed | 5 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Consent withdrawal | 4 | 4 |
Study participants received dapagliflozin 10 mg or matching placebo, given once daily in addition to SoC. Overall, the mean study duration was 12.0 months (time in study until last visit) with an accumulated 4023.9 participant-years. The maximum study duration for any participant was 29 months. "Number of Events" for NYHA corresponds to the number of participants with a non-missing value for NYHA functional class at the last visit, and that all participants with a non-missing value take part in the analysis comparing their NYHA class value with all other participants with a NYHA value, according to the win-ratio method.
| Participants | Dapa 10 mg | Placebo |
|---|---|---|
| The hierachical composite endpoint of all components | 1990 | 1970 |
| Death, adjudicated | 41 | 33 |
| Hospitalisation due to HF | 32 | 41 |
| Non-fatal MI | 29 | 32 |
| AF/Flutter event | 8 | 15 |
| New onset of T2DM | 40 | 74 |
| NYHA Classification at last visit, measuring limitations of physical activity | 1839 | 1773 |
| Body Weight decrease of at least 5% at last visit | 684 | 468 |
Collected over Time frame was from date of randomization and up to and including last day in study, up to 29 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapa 10 mg | 41/2,019 (2%) | 449/2,019 (22.2%) | 0/2,019 (0%) |
| Placebo | 33/1,998 (1.7%) | 404/1,998 (20.2%) | 0/1,998 (0%) |
| Event | Dapa 10 mg | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 40/2019 | 39/1998 |
| Non-cardiac chest painGeneral disorders | 39/2019 | 30/1998 |
| Acute myocardial infarctionCardiac disorders | 36/2019 | 36/1998 |
| Angina pectorisCardiac disorders | 33/2019 | 32/1998 |
| Chest painGeneral disorders | 16/2019 | 24/1998 |
| PneumoniaInfections and infestations | 22/2019 | 15/1998 |
| Angina unstableCardiac disorders | 20/2019 | 17/1998 |
| Atrial fibrillationCardiac disorders | 11/2019 | 18/1998 |
| Acute kidney injuryRenal and urinary disorders | 14/2019 | 16/1998 |
| SyncopeNervous system disorders | 14/2019 | 10/1998 |
| Age, Continuous(Years) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Age (Years) | 63.0 ± 11.06 | 62.8 ± 10.64 | 62.9 ± 10.85 |
| Age, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| >65 years | 831 | 799 | 1630 |
| <=65 years | 1188 | 1199 | 2387 |
| Sex: Female, Male(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| Female | 388 | 419 | 807 |
| Male | 1631 | 1579 | 3210 |
| Race/Ethnicity, Customized(Participants) | Dapa 10 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 64 | 52 | 116 |
| Black or African American | 8 | 15 | 23 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| Other | 40 | 37 | 77 |
| White | 1905 | 1893 | 3798 |
| MISSING | 2 | 1 | 3 |
Showing the first 100 of 103 sites across 2 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Dec 2020 to primary completion in Jul 2023, 30 months.
Results were first posted in Mar 2025, 1 year 8 months after primary completion.
Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 30 months is below that.
Counting every sponsor, half of 151 studies reached it within 39 months; a quarter within 25 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin